The protein was named for the wrong job. In 1992, Tasuku Honjo’s group at Kyoto University was hunting for genes tied to cell death in T cells and cloned a new one. They called it programmed death-1, or PD-1. The name stuck, even though the... Continue reading
Return to previous page
Category: Articles
For years, chemotherapy was the backbone of triple-negative breast cancer (TNBC) treatment because the disease lacked the molecular targets that transformed treatment in other breast cancer subtypes. That treatment paradigm is no longer the whole story. TNBC has become one of the most active areas... Continue reading
Rare disease markets have an odd commercial paradox built into them: the patient population is tiny, but the market opportunity can still be substantial. That’s what makes forecasting them fundamentally different from forecasting a conventional primary care or high-prevalence therapy market. A forecast built mainly... Continue reading
Patients with severe Gorlin syndrome can face repeated surgeries year after year, many of them on the face. Each one can leave a scar, and a face only has so much tissue to spare. Most people meet basal cell carcinoma (BCC) once: a suspicious spot,... Continue reading
In pharma, more data doesn’t always mean better answers. Secondary research can tell a team what has happened in a market, such as prescription trends, treatment shares, clinical developments, competitor activity, patient populations, and market size. But when a commercial, medical, development, or market access... Continue reading
Every drug development program starts with a hypothesis about the product it hopes to become. The Target Product Profile (TPP) is where that hypothesis is written down: the intended indication, the efficacy and safety thresholds, the dosing and administration, and the differentiation the asset needs... Continue reading
There used to be a simple rule in pharma: scientists built the drug, clinical teams proved it worked, and health economists showed up near the end to do the math. Run the trial, demonstrate efficacy, calculate the cost per quality-adjusted life year, build the reimbursement... Continue reading
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metastatic disease was often approached with the expectation of relatively short disease control. That picture has changed... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
